Sienna Biopharma: Tumbles as psoriasis treatment fails mid-stage study

Sienna Biopharmaceuticals

03/12/2018 15:54

** Drug developer's shares  SNNA.O  fall 31 pct to all-time
low of $6.95; Stock 3rd-biggest pct loser across U.S. exchanges
    ** Company's psoriasis treatment SNA-120 fails to meet main
goal of showing statistically significant reduction in desire to
itch in mid-stage trial  urn:newsml:reuters.com:*:nGNXbWHPgX
    ** SNA-120 met secondary goal of clearing psoriatic plaques,
27 pct of patients showed 75 pct reduction
    ** SNNA to start late-stage trial in 2019 H2
    ** Including session losses, stock down 59 pct this year

 (Reporting by Saumya Sibi Joseph in Bengaluru)
 ((Reuters Messaging:
saumya.joseph.thomsonreuters.com@reuters.net))